The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study von Goring, S M, Wilson, J B, Risebrough, N R, Gallagher, J, Carroll, S, Heap, K J, Obradovic, M, Loebinger, M R, Diel, R

Volltext

The cost of Mycobacterium avium complex lung disease in Canada, France, Germany, and the United Kingdom: a nationally representative observational study von Goring, SM, Wilson, JB, Risebrough, NR, Gallagher, J, Carroll, S, Heap, KJ, Obradovic, M, Loebinger, MR, Diel, R

Volltext

Superplasticity in a dilute zinc-aluminum alloy von Cook, R.C., Risebrough, N.R.

Volltext

EE708 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Aclidinium/Formoterol (ACL/FOR) in Patients with COPD in the United Kingdom von Shah, D., Martin, A., Kendall, R., Noorduyn, S.G., Dasari, P., Risebrough, N., Ismaila, A.

Volltext

EE711 Cost-Effectiveness of Umeclidinium/Vilanterol (UMEC/VI) Versus Tiotropium/Olodaterol (TIO/OLO) in Patients With COPD: United Kingdom Payer Perspective von Kendall, R., Martin, A., Shah, D., Noorduyn, S.G., Dasari, P., Risebrough, N., Ismaila, A.

Volltext

Single-Inhaler Triple Therapy in Patients with Advanced COPD: Bayesian Modeling of the Healthcare Resource Utilization Data and Associated Costs from the IMPACT Trial von Gabrio, Andrea, Gunsoy, Necdet B, Baio, Gianluca, Martin, Alan, Paly, Victoria F, Risebrough, Nancy, Halpin, David MG, Singh, Dave, Wise, Robert A, Han, MeiLan K, Martinez, Fernando J, Criner, Gerard J, Martin, Neil, Lipson, David A, Ismaila, Afisi S

Volltext

Cost-Effectiveness of Single- versus Multiple-Inhaler Triple Therapy in a UK COPD Population: The INTREPID Trial von Halpin, David MG, Kendall, Robyn, Shukla, Soham, Martin, Alan, Shah, Dhvani, Midwinter, Dawn, Beeh, Kai M, Kocks, Janwillem WH, Jones, Paul W, Compton, Chris, Risebrough, Nancy A, Ismaila, Afisi S

Volltext

EE648 Economic Analysis of New Single-Inhaler Triple Therapies in Patients With COPD in the UK von Cai, R, Martin, A, Ge, Y, Risebrough, N, Sharma, R, Haeussler, K, Compton, C, Halpin, D, Ismaila, AS

Volltext

POSA40 Cost-Effectiveness of Single-Inhaler Triple Therapy (FF/UMEC/VI) Versus Tiotropium Monotherapy in Patients with COPD in the UK von Martin, A, Shah, D, Shukla, S, Kendall, R, Risebrough, NA, Compton, C, Ismaila, A

Volltext

Economic Evaluation of Umeclidinium/Vilanterol versus Umeclidinium or Salmeterol in Symptomatic Non-Exacerbating Patients with COPD from a UK Perspective Using the GALAXY Model von Shukla, Soham, Shah, Dhvani, Martin, Alan, Risebrough, Nancy A., Kendall, Robyn, Vogelmeier, Claus F., Boucot, Isabelle, Tombs, Lee, Bjermer, Leif, Jones, Paul W., Kerwin, Edward, Compton, Chris, Maltais, Francois, Lipson, David A., Ismaila, Afisi

Volltext

Cost-effectiveness in Canada of azacitidine for the treatment of higher-risk myelodysplastic syndromes von Levy, A R, Zou, D, Risebrough, N, Buckstein, R, Kim, T, Brereton, N

Volltext

Validating A Model To Predict Disease Progression Outcomes In Patients With COPD von Risebrough, N.A, Briggs, A, Baker, T.M, Exuzides, A, Colby, C, Rutten van-Molken, M, Gonzalez McQuire, S, Lomas, D, Muellerova, H, Tal-Singer, R, Ismaila, A

Volltext

Abstract P6-07-02: Pharmacoeconomic evaluation of denosumab for the treatment of bone metastases in patients with advanced breast cancer in Canada von Habib, MJ, Risebrough, N, Moore, P, Kendall, R, Li, CM, Goeree, R

Volltext

PRM260 - A Cost-Effective Enhanced Retrospective Observational Study Methodology to Capture Economic Burden Evidence in a Rare Disease Using Non-Tuberculous Mycobacteria Infection... von Gallagher, JR, McDermott, KJ, Risebrough, N, Heap, KJ, Watch, J

Volltext

PRS20 - The Economic Burden of Non-Tuberculous Mycobacterial Pulmonary Disease In Canada, France, United Kingdom And Germany von Goring, SM, Risebrough, N, Wilson, JB, Watch, J, Gallagher, JR, Heap, KJ, Carroll, S, Obradovic, M

Volltext

The Economic Burden of Non-Tuberculous Mycobacterial Pulmonary Disease In Canada, France, United Kingdom And Germany von Goring, SM, Risebrough, N, Wilson, JB, Watch, J, Gallagher, JR, Heap, KJ, Carroll, S, Obradovic, M

Volltext

The Cost of Remaining NTM Positive: Health Care Utilization and Costs In A Sample of Patients with Refractory Pulmonary Disease Due To Mycobacterium Avium Complex In Canada, German... von Goring, SM, Risebrough, N, Wilson, JB, Watch, J, Gallagher, JR, Heap, KJ, Carroll, S, Obradovic, M

Volltext

PRS21 - The Cost of Remaining NTM Positive: Health Care Utilization and Costs In A Sample of Patients with Refractory Pulmonary Disease Due To Mycobacterium Avium Complex In Canada... von Goring, SM, Risebrough, N, Wilson, JB, Watch, J, Gallagher, JR, Heap, KJ, Carroll, S, Obradovic, M

Volltext

Patient Heterogeneity In Cost-Effectiveness Models for Chronic Obstructive Pulmonary Disease (Copd): are Current Models Suitable to Evaluate Personalized Medicine von Hoogendoorn, M, Feenstra, T, Asukai, Y, Briggs, A, Borg, S, dal Negro, R, Hansen, RN, Jansson, S, Wacker, M, Risebrough, N, Samyshkin, Y, Leidl, R, Rutten van-Mölken, M

Volltext

A Cost-Effective Enhanced Retrospective Observational Study Methodology to Capture Economic Burden Evidence in a Rare Disease Using Non-Tuberculous Mycobacteria Infection as a Mode... von Gallagher, JR, McDermott, KJ, Risebrough, N, Heap, KJ, Watch, J

Volltext